Science Advisory Board to the National Center for Toxicological Research; Notice of Meeting, 43453 [E8-17136]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 144 / Friday, July 25, 2008 / Notices
and will not be permitted to attend the
Council meeting.
All persons entering the building
must pass through a metal detector. In
addition, all items brought to the CMS
Central Office, whether personal or for
the purpose of presentation, are subject
to inspection. We cannot assume
responsibility for coordinating the
receipt, transfer, transport, storage, setup, safety, or timely arrival of any
personal belongings or items used for
the purpose of presentation.
Individuals requiring sign language
interpretation or other special
accommodation must contact the DFO
via the contact information specified in
the FOR FUTHER INFORMATION CONTACT
section of this notice by the date listed
in the DATES section of this notice.
Authority: Section 1868 of the Social
Security Act (42 U.S.C. 1395ee) and section
10(a) of Pub. L. 92–463 (5 U.S.C. App. 2,
section 10(a)).
Dated: July 8, 2008.
Kerry Weems,
Acting Administrator, Centers for Medicare
& Medicaid Services.
[FR Doc. E8–17057 Filed 7–24–08; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Science Advisory Board to the
National Center for Toxicological
Research; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
mstockstill on PROD1PC66 with NOTICES
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). At least one portion of the
meeting will be closed to the public.
Name of Committee: Science
Advisory Board (SAB) to the National
Center for Toxicological Research
(NCTR).
General Function of the Committee:
The Board advises the Director, NCTR,
in establishing, implementing and
evaluating the research programs that
assist the Commissioner of Food and
Drugs in fulfilling his responsibilities.
The Board provides an extra-agency
review in ensuring that the research
programs at NCTR are scientifically
sound and pertinent.
Date and Time: The meeting will be
held on August 12, 2008, from 8:30 a.m.
to 4:30 p.m. and on August 13, 2008,
from 8 a.m. to 1 p.m.
Location: August 12, 2008, NCTR SAB
Conference Room B–12, 3900 NCTR Dr.,
VerDate Aug<31>2005
17:15 Jul 24, 2008
Jkt 214001
Jefferson, AR 72079. August 13, 2008,
University of Arkansas for Medical
Sciences, Stevens Spine Center, Hamlin
Board Room, 501 Jack Stevens Dr., Little
Rock, AR 72205.
Contact Person: Margaret Miller,
Designated Federal Official, National
Center for Toxicological Research (HFT–
10), Food and Drug Administration,
5600 Fishers Lane, rm. 9C–05,
Rockville, MD 20857, 301–827–6693, or
FDA Advisory Committee Information
Line, 1–800–741–8138 (301–443–0572
in the Washington, DC area), code 301–
451–2559. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: On August 12, 2008, the SAB
will hear presentations from the NCTR
Divisions that will update them on
ongoing research activities. The SAB
will be presented with the responses to
two evaluations, one of the Division of
Microbiology and one of the Division of
Biochemical Toxicology. The evaluation
of the Division of Microbiology was the
product of an on-site review visit
conducted of the Division in August
2007. The evaluation of the Division of
Biochemical Toxicology was the
product of an on-site review in April
2008. The responses will address the
issues raised and recommendations
made by the site visit teams. On August
13, 2008, the NCTR Director will
provide a Center-wide update on
scientific endeavors and will discuss the
NCTR realignment and strategic focus.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/ohrms/
dockets/ac/acmenu.htm, click on the
year 2008 and scroll down to the
appropriate advisory committee link.
Procedure: On August 12, 2008, from
8:30 a.m. to 4:30 p.m., and August 13,
2008, from 8 a.m. to 10:30 a.m., the
meeting is open to the public. Interested
persons may present data, information,
or views, orally or in writing, on issues
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
43453
pending before the committee. Written
submissions may be made to the contact
person on or before August 5, 2008. Oral
presentations from the public will be
scheduled on August 12, 2008, between
approximately 12:30 p.m. to 1:30 p.m.
Those desiring to make formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before August 1,
2008. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by August 4, 2008.
Closed Committee Deliberations: On
August 13, 2008, from approximately 11
a.m. to 1 p.m., the meeting will be
closed to permit discussion where
disclosure would constitute a clearly
unwarranted invasion of personal
privacy (5 U.S.C. 552b(c) (6)). This
portion of the meeting will be closed to
permit discussion of issues related to
personnel progress and promotion.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Margaret
Miller at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/oc/advisory/
default.htm for procedures on public
conduct during advisory committee
meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: July 17, 2008.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E8–17136 Filed 7–24–08; 8:45 am]
BILLING CODE 4160–01–S
E:\FR\FM\25JYN1.SGM
25JYN1
]]>Agencies
[Federal Register Volume 73, Number 144 (Friday, July 25, 2008)]
[Notices]
[Page 43453]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-17136]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Science Advisory Board to the National Center for Toxicological
Research; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). At least one
portion of the meeting will be closed to the public.
Name of Committee: Science Advisory Board (SAB) to the National
Center for Toxicological Research (NCTR).
General Function of the Committee: The Board advises the Director,
NCTR, in establishing, implementing and evaluating the research
programs that assist the Commissioner of Food and Drugs in fulfilling
his responsibilities. The Board provides an extra-agency review in
ensuring that the research programs at NCTR are scientifically sound
and pertinent.
Date and Time: The meeting will be held on August 12, 2008, from
8:30 a.m. to 4:30 p.m. and on August 13, 2008, from 8 a.m. to 1 p.m.
Location: August 12, 2008, NCTR SAB Conference Room B-12, 3900 NCTR
Dr., Jefferson, AR 72079. August 13, 2008, University of Arkansas for
Medical Sciences, Stevens Spine Center, Hamlin Board Room, 501 Jack
Stevens Dr., Little Rock, AR 72205.
Contact Person: Margaret Miller, Designated Federal Official,
National Center for Toxicological Research (HFT-10), Food and Drug
Administration, 5600 Fishers Lane, rm. 9C-05, Rockville, MD 20857, 301-
827-6693, or FDA Advisory Committee Information Line, 1-800-741-8138
(301-443-0572 in the Washington, DC area), code 301-451-2559. Please
call the Information Line for up-to-date information on this meeting. A
notice in the Federal Register about last minute modifications that
impact a previously announced advisory committee meeting cannot always
be published quickly enough to provide timely notice. Therefore, you
should always check the agency's Web site and call the appropriate
advisory committee hot line/phone line to learn about possible
modifications before coming to the meeting.
Agenda: On August 12, 2008, the SAB will hear presentations from
the NCTR Divisions that will update them on ongoing research
activities. The SAB will be presented with the responses to two
evaluations, one of the Division of Microbiology and one of the
Division of Biochemical Toxicology. The evaluation of the Division of
Microbiology was the product of an on-site review visit conducted of
the Division in August 2007. The evaluation of the Division of
Biochemical Toxicology was the product of an on-site review in April
2008. The responses will address the issues raised and recommendations
made by the site visit teams. On August 13, 2008, the NCTR Director
will provide a Center-wide update on scientific endeavors and will
discuss the NCTR realignment and strategic focus.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/ohrms/dockets/ac/acmenu.htm, click on
the year 2008 and scroll down to the appropriate advisory committee
link.
Procedure: On August 12, 2008, from 8:30 a.m. to 4:30 p.m., and
August 13, 2008, from 8 a.m. to 10:30 a.m., the meeting is open to the
public. Interested persons may present data, information, or views,
orally or in writing, on issues pending before the committee. Written
submissions may be made to the contact person on or before August 5,
2008. Oral presentations from the public will be scheduled on August
12, 2008, between approximately 12:30 p.m. to 1:30 p.m. Those desiring
to make formal oral presentations should notify the contact person and
submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation on or before August 1, 2008. Time allotted for
each presentation may be limited. If the number of registrants
requesting to speak is greater than can be reasonably accommodated
during the scheduled open public hearing session, FDA may conduct a
lottery to determine the speakers for the scheduled open public hearing
session. The contact person will notify interested persons regarding
their request to speak by August 4, 2008.
Closed Committee Deliberations: On August 13, 2008, from
approximately 11 a.m. to 1 p.m., the meeting will be closed to permit
discussion where disclosure would constitute a clearly unwarranted
invasion of personal privacy (5 U.S.C. 552b(c) (6)). This portion of
the meeting will be closed to permit discussion of issues related to
personnel progress and promotion.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Margaret Miller at
least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/oc/advisory/
default.htm for procedures on public conduct during advisory committee
meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: July 17, 2008.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E8-17136 Filed 7-24-08; 8:45 am]
BILLING CODE 4160-01-S
